Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and ...

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and ...

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology

Renovaro closes merger transaction with BioSymetrics

This follows the company’s February announcement of a definitive merger agreement signed with BioSymetrics. This merger aims to bolster Renovaro’s data analysis and biomarker discovery capabilities, while also The post Renovaro closes merger transaction with BioSymetrics appeared first on Pharmaceutical Business review.

Major AI Breakthrough: Renovaro-BioSymetrics Merger Creates Powerhouse in Precision Medicine

Strategic merger combines AI-powered drug discovery platform with established pharma partnerships. Expands into neurology while advancing oncology programs.

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities - PressReach

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md. and BOSTON and ROLLE, Switzerland, April 8, 2025 /PRNewswire/ — Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker dis…